MAP1B

Across TCGA pan-cancer cohorts, MAP1B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAP1B data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAP1B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP1B expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where MAP1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.545	0.864	.006	26	view →
PDAC	DFS	Quartile	All	0.840	0.606	.005	21	view →
GBM	OS	Quartile	All	0.338	0.693	.001	19	view →
LUAD	DFS	Tertile	All	0.901	0.983	.002	15	view →
LSCC	OS	Tertile	All	0.836	0.935	.041	3	view →
HNSC	DFS	Quartile	II,III,IV	0.527	0.773	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAP1B–CCRCC (DFS)

Open the CCRCC breakdown →